The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured over the first 24 hours, with patients completing the study after 72 hours Dr. Stuart Goldstein , a world-renowned nephrologist, is the first physician to enroll a patient in the NEPHRO CRRT study SAN MATEO, Calif. , Aug.
19, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH ), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the first patient has been enrolled in the NEPHRO CRRT study. The NEPHRO CRRT registrational study will enroll 166 patients undergoing continuous renal replacement therapy (CRRT) at up to 14 clinical sites across the United States .
The primary endpoint of the study is the mean post-filter activated clotting time for circuits infused with nafamostat versus placebo over the first 24 hours. "We are excited to be able to offer participation in this nafamostat study to our patients requiring CRRT," stated Stuart Goldstein, M.D.
, Professor of Pediatrics and Director of the Center for Acute Care Nephrology at Cincinnati Children's Hospital Medical Center. "Nafamostat, if approved following this trial, will be a valuable addition to our anticoagulant options for many patients." "We are pleased the first patient was enrolled in the study l.